Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
According to a report from Reuters and a media release on the Amgen web site, the European Medicines Agency (EMEA) has approved denosumab (Prolia®) for marketing in Europe. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: denosumab, Prolia | 2 Comments »
According to a company media release issued last Friday, Amgen has filed a second new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for approval of denosumab (a RANK-L inhibitor to be known commercially as Prolia®). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: Amgen, approval, denosumab, FDA, Prolia | Leave a Comment »
In today’s news reports we note new articles dealing with:
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: bisphosphonate, dasatinib, denosumab, focal therapy, Gleason, saracatinib, tertiary, zoledronate | 7 Comments »
The FDA’s advisory panel has apparently recommended approval of denosumab, but only for some of the indications that were being requested by the manufacturer. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: denosumab | Leave a Comment »
Tomorrow (Thursday) an advisory committee to the US Food and Drug Administration (FDA) meets to decide whether to recommend approval of Amgen’s new RANK-L inhibitor, denosumab, which offers an entirely new mechanism for the reduction of the risk of fractures and other skeletal related events (SREs) caused by long term hormone therapy (both in patients with breast cancer and those with prostate cancer). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: denosumab, fractures | Leave a Comment »
Two important papers presented this afternoon addressed data on the use of toremifene and denosumab on the bones of men receiving treatment with androgen deprivation therapy (ADT). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation therapy, bone mineral denisty, denosumab, fractures, toremifene | Leave a Comment »
There are six new reports in today’s news, of which the most immediately important would seem to be:
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active suirveillance, cancer anxiety, denosumab, forkhead transcription factors, FOX factors, hormone therapy, MDV3100, testosterone | Leave a Comment »
Today’s important news reports address:
Filed under: Drugs in development, Management, Treatment | Tagged: antiandrogen, apoptosis, approval, arteries, brachytherapy, denosumab, iodine-125, long-term, lymphocyte, radiation therapy, stiffening, survival, toremifene, toxicity | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site